{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:14:39Z","timestamp":1781676879591,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jpba.2020.113181","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T11:37:17Z","timestamp":1581939437000},"page":"113181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Validation of an assay for quantifying ganciclovir in dried blood spots"],"prefix":"10.1016","volume":"184","author":[{"given":"Joseph E.","family":"Rower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Nielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jpba.2020.113181_bib0005","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1473-3099(12)70197-4","article-title":"Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation","volume":"12","author":"Griffiths","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2020.113181_bib0010","series-title":"Vaccines for the 21st Century: A Tool for Decision Making","author":"Stratton","year":"2001"},{"issue":"14","key":"10.1016\/j.jpba.2020.113181_bib0015","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1986.03380140074025","article-title":"Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome","volume":"256","author":"Stagno","year":"1986","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jpba.2020.113181_bib0020","first-page":"2463","article-title":"Valganciclovir for congenital cytomegalovirus","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jpba.2020.113181_bib0025","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jpba.2020.113181_bib0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jpba.2020.113181_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J. Pediatr."},{"issue":"12","key":"10.1016\/j.jpba.2020.113181_bib0040","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10096-009-0806-5","article-title":"Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection","volume":"28","author":"Lombardi","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jpba.2020.113181_bib0045","first-page":"208","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection","volume":"14","author":"Stronati","year":"2013","journal-title":"Curr. Drug Metab."},{"issue":"6","key":"10.1016\/j.jpba.2020.113181_bib0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1345\/aph.1A393","article-title":"Valganciclovir: an advance in cytomegalovirus therapeutics","volume":"36","author":"Cocohoba","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.jpba.2020.113181_bib0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.clpt.6100150","article-title":"Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation","volume":"81","author":"Acosta","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jpba.2020.113181_bib0060","first-page":"364","article-title":"Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir","volume":"33","author":"Jansen CFM","year":"2005","journal-title":"J. Perinat. Med."},{"issue":"5","key":"10.1016\/j.jpba.2020.113181_bib0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.inf.0000261111.90075.4d","article-title":"Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants","volume":"26","author":"Galli","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"1","key":"10.1016\/j.jpba.2020.113181_bib0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.jp.7211854","article-title":"Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant","volume":"28","author":"M\u00fcller","year":"2008","journal-title":"J. Perinatol."},{"issue":"7","key":"10.1016\/j.jpba.2020.113181_bib0075","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0029-1234076","article-title":"Oral valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age","volume":"221","author":"Hilgendorff","year":"2009","journal-title":"Klin. P\u00e4diatr."},{"issue":"3","key":"10.1016\/j.jpba.2020.113181_bib0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mas.21441","article-title":"The use of mass spectrometry to analyze dried blood spots","volume":"35","author":"Wagner","year":"2016","journal-title":"Mass Spectrom. Rev."},{"issue":"11","key":"10.1016\/j.jpba.2020.113181_bib0085","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.jpba.2020.113181_bib0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/adc.2009.177592","article-title":"Facilitating pharmacokinetic studies in children: a new use of dried blood spots","volume":"95","author":"Patel","year":"2010","journal-title":"Arch. Dis. Child."},{"issue":"4","key":"10.1016\/j.jpba.2020.113181_bib0095","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/ac8022839","article-title":"Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method","volume":"81","author":"Spooner","year":"2009","journal-title":"Anal. Chem."},{"issue":"13","key":"10.1016\/j.jpba.2020.113181_bib0100","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2212MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"issue":"11","key":"10.1016\/j.jpba.2020.113181_bib0105","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/AAC.00085-09","article-title":"Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus","volume":"53","author":"Caldes","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2020.113181_bib0110","article-title":"Population pharmacokinetics of ganciclovir in critically Ill patients","author":"Krens","year":"2019","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.jpba.2020.113181_bib0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchromb.2006.10.053","article-title":"A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC\/MS\/MS","volume":"848","author":"Xu","year":"2007","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.jpba.2020.113181_bib0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/(SICI)1099-0801(200004)14:2<93::AID-BMC932>3.0.CO;2-0","article-title":"A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography\/selected reaction monitoring\/mass spectrometry","volume":"14","author":"Xu","year":"2000","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2020.113181_bib0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cca.2013.09.049","article-title":"Measurement of ganciclovir concentration in human plasma by ultra-performance liquid chromatography\u2013tandem mass spectrometry","volume":"427","author":"Rigo-Bonnin","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"5\u20136","key":"10.1016\/j.jpba.2020.113181_bib0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jchromb.2010.12.033","article-title":"Determination of ganciclovir and its prodrug valganciclovir by hydrophilic interaction liquid chromatography\u2013tandem mass spectrometry","volume":"879","author":"Heinig","year":"2011","journal-title":"J. Chromatogr. B"},{"issue":"10\u201311","key":"10.1016\/j.jpba.2020.113181_bib0135","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.clinbiochem.2011.04.003","article-title":"Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection","volume":"44","author":"Singh","year":"2011","journal-title":"Clin. Biochem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519322162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519322162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:02:37Z","timestamp":1760000557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519322162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":27,"alternative-id":["S0731708519322162"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113181","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of an assay for quantifying ganciclovir in dried blood spots","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113181"}}